Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is a vertically-integrated developer and manufacturer of generic and specialty pharmaceutical products. Co-founded by Chirag and Chintu Patel in 2002, Amneal was privately-held for the first 15 years of its history. Over that period, the company invested extensively in R&D resources, manufacturing infrastructure and front-end distribution, growing revenue to over $1 billion. In May 2018, Amneal completed an all-equity business combination with Impax Laboratories, Inc. (formerly NYSE: IPXL). The transaction created the 5th largest U.S. generic drug company with over $2 billion in annual revenue and gave Amneal an entree to the high-margin specialty pharma business. Upon close of the transaction, the combined entity began trading on the New York Stock Exchange under the ticker AMRX.